<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476017</url>
  </required_header>
  <id_info>
    <org_study_id>718-CNP-201</org_study_id>
    <nct_id>NCT04476017</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)</brief_title>
  <official_title>An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sage Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sage Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this two-part study is to evaluate the safety and tolerability of&#xD;
      SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants&#xD;
      with PD-MCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Part A: up to Day 28; Part B: up to Day 42</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE is an AE that occurs after the first administration of a study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements</measure>
    <time_frame>Part A: up to Day 28; Part B: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Laboratory Assessments</measure>
    <time_frame>Part A: up to Day 28; Part B: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements</measure>
    <time_frame>Part A: up to Day 28; Part B: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Baseline for Responses on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Part A: Baseline and Days 1, 7, 14, and 28; Part B: Baseline and Days 1, 7, 14, 21, 28, 35, and 42</time_frame>
    <description>The C-SSRS scale consists of a baseline evaluation (at screening) that assesses the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Part A: SAGE-718</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SAGE-718 tablets, once daily with food in the morning for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SAGE-718</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SAGE-718 tablets, once daily with food in the morning for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAGE-718</intervention_name>
    <description>SAGE-718 oral tablets.</description>
    <arm_group_label>Part A: SAGE-718</arm_group_label>
    <arm_group_label>Part B: SAGE-718</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the following criteria for PD-MCI: Have a confirmed diagnosis of idiopathic PD&#xD;
             according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria; Meet&#xD;
             MDS Task Force Criteria for MCI in PD.&#xD;
&#xD;
          2. Have a score of 20 to 25 (inclusive) on the Montreal Cognitive Assessment (MoCA) at&#xD;
             Screening.&#xD;
&#xD;
          3. Meet criteria for Hoehn &amp; Yahr Stage I to III (mild to moderate motor severity) at&#xD;
             Screening.&#xD;
&#xD;
          4. Have stable motor symptoms for at least 4 weeks prior to screening, in the opinion of&#xD;
             the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a diagnosis of dementia of any etiology, including but not limited to: Dementia&#xD;
             associated with PD (probable or possible), Dementia with Lewy Bodies, Alzheimer's&#xD;
             Dementia, and Vascular Dementia.&#xD;
&#xD;
          2. Have any indication of parkinsonism other than idiopathic PD.&#xD;
&#xD;
          3. In the opinion of the investigator, be experiencing unpredictable fluctuations in&#xD;
             motor and/or nonmotor symptoms associated with PD.&#xD;
&#xD;
          4. Have an ongoing central nervous system condition other than idiopathic PD, including&#xD;
             active neurologic and/or nonremitted psychiatric disorders, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          5. Have a history of brain surgery, deep brain stimulation, a significant head injury&#xD;
             causing loss of consciousness greater than 30 minutes, or hospitalization due to a&#xD;
             brain injury.&#xD;
&#xD;
          6. Have experienced significant psychotic symptoms within the past 3 months, including&#xD;
             those associated with PD medications, as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aaron Koenig</last_name>
    <phone>617-949-5576</phone>
    <email>Aaron.koenig@sagerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Cognitive Dysfunction</keyword>
  <keyword>SAGE-718</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

